Kymera Therapeutics(KYMR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update Sanofi plans to expand KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to accelerate overall development timelines following interim analysis of safety and efficacy data STAT6 degrader program on track to initiate Phase 1 in second half of 2024 with data in first half of 2025; TYK2 degrader program on track to initiate and complete Phase 1 in 2025 Data from KT-253 (MDM2) and KT-333 ( ...